Related Experiment Video
Updated: Jul 7, 2026

Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats
Published on: March 7, 2025
[Anticoagulation and vitreoretinal surgery]
1Hôtel-Dieu, Service d'Ophtalmologie, 1 pl. du Parvis Notre-Dame, 75181 Paris Cédex 04.
Insights
Patients on anticoagulation therapy can safely undergo vitreoretinal surgery without altering their medication. This study found no increased complications, suggesting current anticoagulation management is appropriate for these procedures.
Area of Science:
- Ophthalmology
- Cardiology
- Vascular Surgery
Background:
- Vitreoretinal surgery patients often require anticoagulation therapy.
- Current guidelines for managing anticoagulation during vitreoretinal surgery are lacking.
- Indications for anticoagulation include atrial fibrillation, coronary insufficiency, cerebrovascular disease, deep vein thrombosis, and prosthetic heart valves.
Purpose of the Study:
- To evaluate the safety of continuing anticoagulation therapy in patients undergoing vitreoretinal surgery.
- To determine if preoperative anticoagulation requires modification for vitreoretinal procedures.
Main Methods:
- Sixty patients (mean age 73) on anticoagulation therapy underwent vitreoretinal surgery.
- Patients received either vitamin K antagonists (22) or antiplatelet agents (38).
- Surgery proceeded with standard sub-tenon anesthesia, without altering anticoagulation regimens.
Main Results:
- Only one patient experienced an intraoperative complication (subretinal hemorrhage requiring retinectomy) during a major procedure for retinal detachment.
- No other complications were reported in the study cohort.
- The overall complication rate was low, suggesting safety.
Conclusions:
- Ongoing anticoagulation therapy does not necessitate changes for patients undergoing vitreoretinal surgery.
- Current anticoagulation management appears safe and effective for this patient population.
- Further research may confirm these findings and inform guideline development.
Abstract:
About one-third of patients undergoing vitreoretinal surgery are receiving anticoagulation therapy. There are no consensus guidelines on anticoagulation in this setting. Sixty patients (mean age 73 y) on anticoagulation therapy underwent vitreoretinal surgery. The indications for anticoagulation included atrial fibrillation, coronary insufficiency, cerebrovascular disease, deep vein thrombosis and prosthetic heart valves. Twenty-two patients (36.7%) were treated with vitamin K antagonists and 38 (67.3%) with antiplatelet agents (clopridogel or aspirin). After sub-tenon anesthesia, the surgical procedure was performed as usual, regardless of preoperative treatment and intercurrent disease. One patient who underwent a major procedure for complicated retinal detachment had an intraoperative subretinal hemorrhage requiring retinectomy. No other complications occurred. These results suggest that no change in ongoing anticoagulation therapy is required for patients scheduled for vitreoretinal surgery.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Anticoagulant Drugs: Low-Molecular-Weight Heparins
